Linc01833 drives gemcitabine resistance in non-small cell lung cancer by shielding SLC7A11 from WWP1-mediated ubiquitination and inhibiting ferroptosis
Drug Resistance Updates · 2026-03 · 85 · 101351
DOI: 10.1016/j.drup.2026.101351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-03. Verfasst von Lianli Ni und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; National …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, RNA, Long Noncoding, Lung Neoplasms, Deoxycytidine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Province Natural Science Foundation.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and the leading cause of cancer-related deaths globally. The RNA binding protein Quaking-5 (QKI-5) has been established as a tumor suppressor in NSCLC. Inducing ferroptosis is regarded as an effective therapeutic strategy for cancer treatment, and long non-coding RNA (lncRNA) plays a critical role in the regulation of ferroptosis. However, the relationship between QKI-5-regulated lncRNA and ferroptosis remains uncharacterized in NSCLC. In this study, we discovered that QKI-5 downregulates the oncogenic lncRNA linc01833, which inhibits ferroptosis and promotes NSCLC progression by activating SLC7A11/GPX4 signaling pathway. Mechanistically, QKI-5 negatively regulates the stability of linc01833, leading to increased linc01833 expression in NSCLC. Silencing linc01833 enhanced WW domain-containing E3 ubiquitin protein ligase 1 (WWP1)-mediated ubiquitination of SLC7A11, resulting in decreased SLC7A11 expression, while overexpression of linc01833 produced the opposite effect. Further analyses demonstrated that linc01833 diminished the anti-tumor effect of gemcitabine (GEM) in NSCLC both in vivo and in vitro. Additionally, knocking down linc01833 or SLC7A11 is able to inhibit GEM resistant NSCLC growth. Our findings suggest that targeting linc01833 to induce ferroptosis could enhance the cytotoxic effects of chemotherapeutic agents and may serve as an effective therapeutic strategy for some NSCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; National Key Laboratory of Macromolecular Drug Development and Manufacturing, S…
- Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Cellular and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenz…
- National Key Laboratory of Macromolecular Drug Development and Manufacturing, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Oujiang Laborator…
Förderung
- National Natural Science Foundation of China
- Zhejiang Province Natural Science Foundation
Zitieren
APA
Ni, L., Li, H., Chen, P., Yu, Y., Xie, C., Hong, W., Fang, G., Wan, B., Shen, Y., Zou, P., Zhu, W., Liu, Z., Li, X., & Cui, R. (2026). Linc01833 drives gemcitabine resistance in non-small cell lung cancer by shielding SLC7A11 from WWP1-mediated ubiquitination and inhibiting ferroptosis. Drug Resistance Updates, 85, 101351. https://doi.org/10.1016/j.drup.2026.101351
Vancouver
Ni L, Li H, Chen P, Yu Y, Xie C, Hong W, et al. Linc01833 drives gemcitabine resistance in non-small cell lung cancer by shielding SLC7A11 from WWP1-mediated ubiquitination and inhibiting ferroptosis. Drug Resistance Updates. 2026;85:101351. doi:10.1016/j.drup.2026.101351
BibTeX
@article{Ni2026,
author = {Ni, Lianli and Li, Hailong and Chen, Peipei and Yu, Yun and Xie, Chenjun and Hong, Wenfeng and Fang, Gaowei and Wan, Baohong and Shen, Yiwei and Zou, Peng and Zhu, Wangyu and Liu, Zhiguo and Li, Xiaokun and Cui, Ri},
title = {Linc01833 drives gemcitabine resistance in non-small cell lung cancer by shielding SLC7A11 from WWP1-mediated ubiquitination and inhibiting ferroptosis},
journal = {Drug Resistance Updates},
year = {2026},
volume = {85},
pages = {101351},
doi = {10.1016/j.drup.2026.101351}
}
EUVIMED